This week, B&E participated in the Medlab Middle East 2025 exhibition held in Dubai, gathering with hundreds of new and old customers from around the world to share achievements in cooperation and plan for future development. The company showcased several highly anticipated medical devices, including the I-check handheld blood gas analyzer, KS-402 fully automatic electrolyte analyzer, G21 glycated hemoglobin analyzer, Hemax53+FI fully automatic hematology analyzer, Hemax530Al fully automatic blood analyzer, and CBS5 electrolyte analyzer. These devices attracted attention from customers and industry professionals worldwide with their advanced technology and superior performance.
During the exhibition, B&E not only had in-depth discussions with long-term cooperating distributors to consolidate existing relationships but also communicated effectively with numerous potential distributors, laying a solid foundation for future collaborations. Committed to providing high-quality medical solutions, B&E showcased equipment that is a testament to the company's continuous innovation and R&D efforts.
The I-check handheld blood gas analyzer boasts top-tier technical performance globally, offering convenient, fast, and accurate testing capabilities, making it one of the star products at the exhibition. The KS-402 fully automatic electrolyte analyzer completes sample processing, testing, and data analysis automatically, significantly enhancing laboratory efficiency and winning favor among many customers. Utilizing high-performance liquid chromatography (HPLC), it provides precise and repeatable test results, aiding in early diabetes screening and condition monitoring. The Hemax53+FI fully automatic five-part differential plus fluorescence immunoassay analyzer rapidly identifies inflammatory infection sources, further promoting the effective use of antibiotics.
In response to an increasingly competitive market environment, B&E will continue to uphold its business philosophy of "innovation-driven and quality first", increasing investment in R&D and expanding into international markets. We look forward to working hand in hand with more partners to jointly promote the advancement of global healthcare, safeguarding patients' health.
